WebAt the present time, scientists place a great deal of effort worldwide trying to improve the therapeutic potential of metal complexes of curcumin and curcuminoids. Herein, the synthesis of four homoleptic metal complexes with diacetylcurcumin (DAC), using a ligand designed to prevent the interaction of phenolic groups, rendering metal complexes … WebJun 15, 2024 · Wang et al. indicated that miR-17 targets c-Jun activation domain binding protein 1 (JAB1) to promote tumor growth and cisplatin (DDP) resistance of TNBC [9]. As far as we know, chemotherapy is the standard therapeutic strategy for TNBC, and DDP is the most widely used chemotherapeutic drug for solid tumors.
Rx only PLATINOL - Food and Drug Administration
WebJul 12, 2024 · Cisplatin is a potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in … WebCisplatin is a chemotherapy drug which is used to treat cancers including: sarcoma, small cell lung cancer, germ cell tumors, lymphoma, and ovarian cancer. While it is often … ips chennai conference
Cisplatin 15663-27-1 - ChemicalBook
Cisplatin for injection, USP, a platinum-based drug for intravenous use, is a white to light yellow lyophilized powder. Each vial of Cisplatin for injection, USP contains 50 mg Cisplatin, 450 mg Sodium Chloride, USP, and 500 mg Mannitol, USP. Cisplatin for Injection, USP may contain hydrochloric acid for pH adjustment. … See more Cisplatin for injection, USP: single-dose vials containing 50 mg of Cisplatin as white to light yellow lyophilized powder for reconstitution. See more Cisplatin for injection is contraindicated in patients with severe hypersensitivity to Cisplatin [see Warnings and Precautions (5.4)]. See more WebProduct Details. Off-white to orange powder. Soluble in dimethyl formamide (16mg/ml) or DMSO (10mg/ml); sparingly soluble in water; insoluble in 100% ethanol. Protect from … Webcombination with a fluoropyrimidine (capecitabine or 5-FU) and cisplatin (Study 7). In the trastuzumab plus chemotherapy arm, the initial dose of trastuzumab 8 mg/kg was administered on Day 1 (prior to chemotherapy) followed by 6 mg/kg every 21 days until disease progression. Cisplatin was administered at 80 mg/m on Day 1 and the ips chemical